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Introduction {#sec005}
============

Lenvatinib is a tyrosine kinase inhibitor (TKI) that was approved in Japan in 2018 for first-line treatment of unresectable hepatocellular carcinoma. Unexpected fatigue during lenvatinib treatment has been reported to be present in 30%--75% of the general hepatocellular carcinoma patient population \[[@pone.0229772.ref001], [@pone.0229772.ref002]\]. Fatigue is one of the most common causes of treatment discontinuation because of the patient's subsequent appetite loss, worsened quality of life, depression, and anxiety \[[@pone.0229772.ref001], [@pone.0229772.ref002]\]. The occurrence of fatigue during lenvatinib therapy has been reported to be higher compared with sorafenib, another TKI that is used to treat patients with hepatocellular carcinoma \[[@pone.0229772.ref003]\]. The alleviation of lenvatinib-induced fatigue is, therefore, an increasingly important clinical unmet need in the treatment of patients with hepatocellular carcinoma. However, factors that cause lenvatinib-induced fatigue have not been clarified.

Fatigue is a multidimensional and complex clinical symptom, which involves abnormal adenosine triphosphate synthesis \[[@pone.0229772.ref004]\]. Patients with cancer occasionally experience fatigue and general malaise before and after treatment, which is described as cancer-related fatigue. Although multifactorial and subjective cancer-associated conditions are influenced, decreased serum carnitine levels in patients who are undergoing cisplatin chemotherapy have been reported to be associated with fatigue \[[@pone.0229772.ref005]--[@pone.0229772.ref008]\]. Carnitine has an important biological function in the transport of long-chain fatty acids into the mitochondria for subsequent β-oxidation \[[@pone.0229772.ref009]\]. It also plays a role in eliminating acetyl carnitine, which is formed from excess accumulation of acetyl CoA because of decreased ATP synthesis \[[@pone.0229772.ref009]\]. The kidneys play an important role in maintaining carnitine homeostasis by reabsorbing appropriately 90% of the filtered carnitine at the level of the renal tubular epithelial cells \[[@pone.0229772.ref010],[@pone.0229772.ref011]\]. Carnitine/organic cation transporter (OCTN)2, a sodium-dependent high affinity carnitine transporter, is strongly expressed in kidney, skeletal muscles, heart and placenta \[[@pone.0229772.ref012]\]. It is most abundant in the brush-border membrane of the kidney proximal tubules, where it is mainly involved in carnitine reabsorption \[[@pone.0229772.ref012],[@pone.0229772.ref013]\]. Recent studies have demonstrated that modulation of the OCTN2 transport activity by administered OCTN2 substrate drugs such as oxaliplatin, verapamil, spironolactone, imatinib, and valproate can cause drug-induced secondary carnitine deficiency \[[@pone.0229772.ref013]--[@pone.0229772.ref015]\]. Additionally, a recent *in vitro* study showed that TKIs including imatinib, sorafenib, and sunitinib can inhibit OCTN2 function by appropriately 11%, 23%, and 54%, respectively, because of direct competitive inhibition of human OCTN2 \[[@pone.0229772.ref016]\].

The mechanism by which lenvatinib administration affects carnitine homeostasis remains unknown, and no studies have estimated the relationship between fatigue and carnitine levels during lenvatinib therapy. Therefore, we aimed to analyze plasma and urine carnitine levels and investigate the relationship between these levels and fatigue. Additionally, we explored the role of oral levocarnitine supplementation on fatigue during the lenvatinib treatment in a preliminary study.

Materials and methods {#sec006}
=====================

Patients and treatments {#sec007}
-----------------------

This was a single-center, exploratory, prospective study. This study was approved by the Ethical Review Board of Juntendo University Faculty of Medicine (Jundai-Irin No-2016135) and was performed in accordance with the 1964 Declaration of Helsinki and its later amendments. Written informed consent was obtained from all patients before enrollment. The study period was from February 2019 through November 2019. Patients who were going to receive lenvatinib therapy for unresectable hepatocellular carcinoma were included. No patients who had a history of previous molecular-targeted agent treatment were included. Patients with impaired Eastern Cooperative Oncology Group performance status (PS 2, 3, and 4) were also excluded from the study. Patients received oral lenvatinib (Eisai Co., Ltd., Tokyo, Japan) 8 mg/day (for bodyweight \<60 kg) or 12 mg/day (for bodyweight ≥60 kg) once daily after breakfast.

Adverse event (AE) grades were assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. In accordance with the guidelines for lenvatinib administration, the drug dose was reduced when a patient developed any grade 3 or 4 AE, or any unacceptable CTCAE 4.0 grade 2 AE. The Brief Fatigue Inventory (BFI), a nine-item questionnaire for the assessment of fatigue severity, was used to evaluate fatigue \[[@pone.0229772.ref017],[@pone.0229772.ref018]\]. Patients with fatigue of over CTCAE 4.0 Grade 2, which is equivalent to a BFI score of over 3--5 using the questionnaire, after 2 or 4 weeks of lenvatinib therapy were administrated levocarnitine 1500 mg per day orally. Those who did not report worse fatigue compared with the baseline received no supplementation. Thyroid function was tested before initiation of lenvatinib therapy and monitored bi-weekly thereafter, and thyroid-replacement medication was adjusted as necessary.

Fasting morning blood and urine samples were collected from patients before starting lenvatinib treatment (day 0), and on the days 3, 7, 14, and 28. Total carnitine and free carnitine (FC) levels in the plasma and urine in all specimens were measured by an enzyme cycling method using an autoanalyzer (JCA-BM8040 series; JEOL, Tokyo, Japan) and acyl carnitine (AC) was calculated as the difference between total carnitine and FC \[[@pone.0229772.ref019]\]. For the analysis, the urinary carnitine concentration was divided by the urinary creatinine concentration to correct for the influence of dilution. The plasma AC-to-FC (AC/FC) ratio was calculated based on the measured values. Therapeutic response was evaluated using enhanced computed tomography that was obtained 6 weeks after starting lenvatinib, in accordance with the modified Response Evaluation Criteria in Solid Tumors (RECIST) \[[@pone.0229772.ref020]\].

Statistical analysis {#sec008}
--------------------

The Wilcoxon signed-rank test was used to compare between the plasma and urinary baseline carnitine levels and each time point (days 3, 7, 14, and 28). To identify differences between the baseline plasma AC/FC ratio and those of each time point after oral lenvatinib administration, a paired sample *t*-test was used after the data were tested for normal distribution using the Shapiro--Wilk normality test. Pearson's correlation coefficient was used to determine the association between BFI and the AC/FC ratio. All statistical analyses were performed using SPSS Statistics for Windows, Version 22 (IBM Corp., Tokyo, Japan). All tests were two-sided, and *p* values \< 0.05 were considered to be statistically significant.

Results {#sec009}
=======

Patient characteristics and dynamic changes in carnitine concentration {#sec010}
----------------------------------------------------------------------

Twenty Japanese patients (five females and 15 males) with a median age of 76 years (range, 63--88 years) were enrolled into the study. The clinical profiles of all patents included in this study are shown in [Table 1](#pone.0229772.t001){ref-type="table"}. The etiology of hepatocellular carcinoma was hepatitis B virus antigen-positive in two patients, hepatitis C virus antibody-positive in eight patients and other causes in 10 patients. The objective response was complete response (CR) in one patients, partial response (PR) in 11 patients, stable disease (SD) in five patients and progressive disease (PD) in three patients, respectively, with an overall response rate of 60% and a disease control rate of 85%.

10.1371/journal.pone.0229772.t001

###### Patient characteristics.

![](pone.0229772.t001){#pone.0229772.t001g}

  Characteristic                                          N = 20
  ------------------------------------------------------- --------------------
  Age, median (years)                                     76 (63--88)
  Male/Female                                             15/5
  ECOG 0/1                                                19/1
  Body weight, median, (kg)                               59.0 (38.6--77)
  Etiology HBV/HCV/NBNC                                   2/8/10
  Starting dose 12/8 mg                                   8/12
  Child-Pugh score 5/6                                    12/8
  BCLC staging B/C                                        20/5
  Extra hepatic spread Yes/No                             4/16
  ALBI grade 1/2a/2b                                      4/10/6
  Albumin, median (g/dL)                                  3.7 (3--4.2)
  Total bilirubin, median (mg/dL)                         0.8 (0.4--1.6)
  Estimated glomerular filtration rate (mL/min/1.73 m2)   61.7 (43.2--101.5)
  Prothrombin time, median (%)                            88 (68--105)
  NH3, median (μg/dL)                                     34 (16--112)
  AFP, median (ng/mL)                                     26.6 (0.9--57200)
  PIVKA-II, median (MAU/mL)                               1470 (15--68600)
  Objective response CR/PR/SD/PD                          1/11/5/3

ECOG: Eastern Cooperative Oncology Group; HBV: hepatitis B virus; HCV; hepatitis C virus; NBNC: non-hepatitis B or C virus; ALBI: Albumin-Bilirubin; AFP: alpha-fetoprotein; PIVKA-II: protein induced by vitamin K absence or antagonist; CR: complete response; PR: partial response, SD: stable disease; PD: progressive disease.

The dynamic changes in plasma and urine FC and AC levels after the start of lenvatinib treatment are illustrated in [Fig 1](#pone.0229772.g001){ref-type="fig"}. The data after initiation of oral levocarnitine supplementation and cessation of the lenvatinib after day 14 were excluded. The plasma FC concentration on days 3 and 7 was significantly higher compared with the baseline carnitine concentrations (*p* = 0.005, *p* = 0.005, respectively) and it returned to near-normal levels 14 and 28 days after the start of therapy ([Fig 1A](#pone.0229772.g001){ref-type="fig"}). However, the plasma AC concentration on days 14 and 28 were significantly higher compared with baseline (*p* = 0.002, *p* = 0.005, respectively). The urine FC-to-creatinine ratio on day 3 was significantly higher compared with baseline levels (*p* = 0.030) and that on day 7 tended to be higher than that of baseline, but the difference was not significant (*p* = 0.057). However, it subsequently returned to normal 14 and 28 days after the start of therapy ([Fig 1B](#pone.0229772.g001){ref-type="fig"}). Additionally, as illustrated in [Fig 2](#pone.0229772.g002){ref-type="fig"}, we found that the percent increase from day 0 in urine to day 7 was significantly correlated with that in plasma (r = 0.545, *p* = 0.013).

![Changes in free and acyl carnitine in plasma creatinine (A) and urine, as assessed by urinary creatinine (B) after starting lenvatinib treatment.\
The box spans data between two quartiles (IQR, interquartile range), and the bold line represents the median. The ends of the whiskers represent the largest and smallest values that are not outliers. Outliers are values between 1.5 and 3 IQRs from the end of the box. \* *p* \< 0.05; versus baseline (Pre).](pone.0229772.g001){#pone.0229772.g001}

![Correlation between the change in plasma and urine free carnitine on day 7 after starting lenvatinib therapy.\
r = 0.545, *p* = 0.013.](pone.0229772.g002){#pone.0229772.g002}

The individual time course of the plasma AC/FC ratio in 20 patients treated with lenvatinib, excluding the data after levocarnitine supplementation or cessation of the lenvatinib, is shown in [Fig 3](#pone.0229772.g003){ref-type="fig"}. The mean and standard error of the plasma AC/FC ratio on days 0, 3, 7, 14, and 28 were 0.207 ± 0.061, 0.165 ± 0.055, 0.185 ± 0.079, 0.292 ± 0.107, and 0.279 ± 0.092, respectively. The value on day 3 was significantly lower compared with baseline (*p* = 0.024). However, the ratio on days 14 and 28 was significantly higher compared with baseline (*p* = 0.001, *p* = 0.003, respectively). On day 28, overt carnitine insufficiency based on the AC/FC ratio \>0.4 \[[@pone.0229772.ref021], [@pone.0229772.ref022]\] was found in 3/20 (15%) patients.

![Time profiles of the plasma acyl-to-free carnitine ratio after starting lenvatinib treatment.\
The heavy line represents the mean with the standard error. AC/FC ratio, AC-to-FC ratio. \* *p* \< 0.05; versus baseline (Pre).](pone.0229772.g003){#pone.0229772.g003}

Relationship between the plasma AC/FC ratio and the Brief Fatigue Inventory {#sec011}
---------------------------------------------------------------------------

We then assessed the correlation between the plasma AC/FC ratio and BFI. At baseline, there was a nearly-significant positive correlation between the two variables ([Fig 4A](#pone.0229772.g004){ref-type="fig"}; r = 0.410, *p* = 0.073). We also found that there was a significant positive correlation between the AC/FC ratio and the BFI differences for each patient between day 14 and day 28 ([Fig 4B and 4C](#pone.0229772.g004){ref-type="fig"}; r = 0.461, *p* = 0.041; r = 0.770, *p* = 0.002, respectively).

![Correlation between the plasma acyl-to-free carnitine ratio and the Brief Fatigue Inventory (BFI) for each patient between baseline (A) and day 14 (B) or 28 (C).\
AC/FC ratio, AC-to-FC ratio; BFI, Brief Fatigue Inventory; ΔBFI, difference in the Brief Fatigue Inventory.](pone.0229772.g004){#pone.0229772.g004}

Changes in the Brief Fatigue Inventory and plasma AC/FC ratio after oral levocarnitine supplementation {#sec012}
------------------------------------------------------------------------------------------------------

During the lenvatinib on or after 4 weeks of the administration, 11 patients (55%) reported fatigue of over CTCAE Grade 2, which was equivalent to a BFI score of greater than 3--5, and the patients received oral levocarnitine supplementation (1500 mg per day) after reporting the maximum fatigue. The change in the BFI and plasma AC/FC ratio among baseline, the day before levocarnitine supplementation, and 4 weeks after the supplementation is shown in [Fig 5](#pone.0229772.g005){ref-type="fig"}. The BFI on the day before levocarnitine supplementation, which was significantly increased compared with baseline (*p* \< 0.001), was significantly reduced at 4 weeks after starting the carnitine supplementation (*p* \< 0.001). Seven of 11 patients (64%) had a dose reduction, but the BFI score improved in four of 11 patients (36%) without a lenvatinib dose reduction. Although the plasma AC/FC ratio on the day before levocarnitine supplementation significantly increased compared with baseline (*p* = 0.002), there was no significant difference between that of the day before supplementation and that of 4 weeks after supplementation (*p* = 0.984).

![Change in the Brief Fatigue Inventory and the plasma acyl-to-free carnitine (AC/FC) ratio among baseline, the day before levocarnitine supplementation, and 4 weeks after the supplementation.\
The thick line represents the mean with the standard error. The solid line represents without a lenvatinib dose reduction, and the dotted line represents with a lenvatinib dose reduction. BFI, Brief Fatigue Inventory; AC/FC ratio, AC-to-FC ratio; *\* p* \< 0.05 versus the day before levocarnitine supplementation.](pone.0229772.g005){#pone.0229772.g005}

Discussion {#sec013}
==========

In this study, we have shown that lenvatinib has the potential to affect plasma and urinary carnitine levels after the start of oral administration.

First, we found that plasma and urinary FC levels increased for 3--7 days after starting lenvatinib administration and the increase in urinary carnitine excretion was related to that of the plasma carnitine levels. Our results suggest that disposition of plasma carnitine is the same as that of urinary carnitine at an early stage after the start of lenvatinib therapy. Second, we showed that, despite no remarkable changes in urinary carnitine levels at steady state such as at days 14 and 28, the plasma AC/FC ratio, which serves as an indicator of carnitine deficiency, increased because of the increase in the plasma AC concentration. Although the mechanism for fluctuation of carnitine disposition is unclear, cellular or intra-mitochondrial uptake of carnitine might be inhibited by lenvatinib administration in terms of increase in plasma carnitine and the increased plasma carnitine levels would lead to increased urinary excretion. Given the carnitine shuttle \[[@pone.0229772.ref023]\], there are two major possible explanations for the increase in plasma AC at steady state. One explanation is that intra-mitochondrial uptake of AC may be reduced if long-chain AC is increased. The second explanation is that acetyl CoA may accumulate in the skeletal muscles and acetyl carnitine metabolism may be impaired in hepatocytes if acetyl carnitine is increased.

Additionally, in this study, we showed that the plasma AC/FC ratio is related to the severity of fatigue. There was a strong correlation between BFI and AC/FC ratio at day 28 existed regardless of the presence or absence of viral hepatitis, whether it was a viral infection or other causes (r = 0.840 and r = 0.773, respectively).

Under normal conditions, 80% of the total plasma carnitine is FC and 20% is AC, with a normal AC/FC ratio of 0.25 \[[@pone.0229772.ref024], [@pone.0229772.ref025]\]. A plasma AC/FC \>0.4 is considered to be abnormal and represents carnitine insufficiency, as previously reported, and this is also included in the Japanese guidelines \[[@pone.0229772.ref021], [@pone.0229772.ref022]\]. Our results show that 15% of the patients were in the category at day 14 and most patients may have latent carnitine insufficiency 14 days after the start of lenvatinib. Anorexia caused by anticancer therapy may reduce oral intake, which may lead to low plasma carnitine levels \[[@pone.0229772.ref005]\]. Because all the included patients did not report appetite loss until 28 days after starting lenvatinib, an increased AC/FC ratio would mainly reflect the development of fatigue.

Previous studies have identified several widely used anticancer drugs as OCTN2 inhibitors, including vinblastine, actinomycin D, and etoposide \[[@pone.0229772.ref015], [@pone.0229772.ref016]\]. Hu et al. reported, in an *in vitro* study, that sorafenib, the first-line TKI for treating patients with hepatocellular carcinoma, can inhibit the OCTN2 function by approximately 23% because of direct competitive inhibition of human OCTN2 \[[@pone.0229772.ref016]\]. Because lenvatinib is also a kinase inhibitor, it may inhibit the OCTN's function, but *in vitro* studies on lenvatinib inhibition of OCTN function have not been performed. However, because more fatigue was reported during lenvatinib therapy compared with sorafenib \[[@pone.0229772.ref003]\], it is possible that lenvatinib's inhibitory effect on OCTN2 is stronger compared with that of sorafenib.

It is crucial for clinicians to manage lenvatinib-induced fatigue, continue the therapy, and achieve a long treatment duration that may lead to improvement in the patient's survival period by maintaining the relative dose intensity \[[@pone.0229772.ref026]\]. The finding that lenvatinib may be more or less associated with secondary drug-induced carnitine insufficiency would lead to an improvement in the quality of pharmacological treatment. To the best of our knowledge, this is the first study to demonstrate the association between carnitine dynamics and fatigue during lenvatinib therapy in patients with hepatocellular carcinoma.

It is plausible that restoration of plasma carnitine levels via carnitine supplementation could ameliorate lenvatinib-induced fatigue. Recent studies showed a decrease in fatigue with levocarnitine supplementation in patients with various types of cancer \[[@pone.0229772.ref007], [@pone.0229772.ref027]\]. In this study, levocarnitine administration in hepatocellular carcinoma patients who are undergoing lenvatinib therapy improved the BFI score, as expected. It should be noted that the BFI score improved in four of 11 patients (36%) without a lenvatinib dose reduction and the AC/FC ratio was decreased in three of four patients.

An improvement in the patients' fatigue would be affected by both carnitine supplementation and various other factors including the placebo effect and tumor shrinkage that result from the antitumor effect of lenvatinib. The AC/FC ratio was not necessarily improved in some patients after the supplementation. This may be because the placebo effect influences the BFI score during lenvatinib treatment. Based on a recent meta-analysis, there is not enough evidence to support the recommendation to use carnitine supplementation for cancer-related fatigue in the oncological clinical setting \[[@pone.0229772.ref028]\]. However, a substantial improvement in fatigue that was observed in patients without a lenvatinib dose reduction during levocarnitine supplementation provides strong support for our finding that lenvatinib therapy caused carnitine insufficiency. The efficacy of carnitine supplementation to patients who were administered lenvatinib requires confirmation in a randomized controlled trial. In addition, it is important to consider the type of patients who are recommended to receive carnitine supplementation. Because the baseline plasma AC/FC ratio of non-responders (SD and PD) tended to be higher compared with that of responders (CR and PR) (*p* = 0.057), it might be better to consider levocarnitine supplementation in patients with a high AC/FC ratio to retain the relative lenvatinib dose intensity.

Throughout the study period, only the plasma AC/FC ratio among all of the markers (plasma FC, plasma AC, urine FC, urine AC levels, and urine AC/FC ratio) was associated with BFI (data not shown). Therefore, only the plasma AC/FC ratio seems to be a useful marker during lenvatinib therapy. As mentioned above, the baseline plasma AC/FC ratio seems to be useful for predicting incomplete treatment with lenvatinib.

Our study has several limitations. First, the number of patients included is limited. Second, because carnitine analyses were measured using an enzyme cycling method, it is not possible to determine whether the increase in AC was long-chain AC or acetyl carnitine. Third, only fatigue was analyzed in this study. Adrenal function, which is reportedly a cause of fatigue during the treatment, was not examined \[[@pone.0229772.ref029]\]. Despite these limitations, our findings may provide evidence that lenvatinib affects carnitine homeostasis, and they suggest that carnitine insufficiency is a major factor in the development of fatigue during the therapy.

In conclusion, our findings suggest that lenvatinib therapy is associated with drug-induced carnitine insufficiency. Therefore, monitoring blood carnitine levels during treatment might be useful for anticipating the development of fatigue. Further research is needed to clarify the role in levocarnitine supplementation for preventing or improving fatigue.
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Yours sincerely,

Hironao Okubo, MD, PhD

Department of Gastroenterology

Juntendo University Nerima Hospital

Response to academic editor

1\) Authors should describe the status of HBsAg and anti-HCV in table 1, and discuss their influence.

Response: Thank you for your valuable comments. In accordance with the comment, we have added information about the etiology, which includes the presence or absence of HBs-Ag/HCV-Ab, in Table 1 and the Discussion section (lines 256--258 as follows:

There was a strong correlation between BFI and AC/FC ratio at day 28 existed regardless of the presence or absence of viral hepatitis, whether it was a viral infection or other causes (r = 0.840 and r = 0.773, respectively).

2\) Major problem is that the number of patients is too small, and authors should increase the number of patients to at least 20.

Response: In accordance with the advice, we added the two most recent cases, and the data from 20 patients were reanalyzed. The revised results further support our conclusion.

\#Response to reviewer 1

1\) In Figure 4, the authors showed the correlation between BFI and AC/FC ratio in Day 14, and Day 28. Please add the figure of the correlation between BFI and AC/FC ratio at baseline. If correlation was not showed at baseline, please discuss the cause of this phenomenon.

Response: In accordance with the comment, we added the data for the correlation between BFI and the AC/FC ratio at baseline to Figure 4 of the revised manuscript. We found that there was a nearly significant positive correlation between the two variables (Fig 4A; r = 0.410, p = 0.073). This description was added to the revised manuscript (lines 200-202).

2\) Please insert reference to discussion section, line 256.

Response: In accordance with the reviewer's advice, we have added the following reference to the Discussion (line 281 in the revised manuscript): Takahashi A, Moriguchi M, Seko Y, Ishikawa H, Yo T, Kimura H, et al. Impact of relative dose intensity of early-phase lenvatinib treatment on therapeutic response in hepatocellular carcinoma. Anticancer Res. 2019;39:5149-56.

\#Response to reviewer 2

1\. As the authors mentioned in the limitations, the study cohort is too small. The reviewer would suggest that the authors evaluate ATP or energy charge level and/or OCTN functions of the patients. Detailed analysis using more parameters or translational experiments might add strength in the study regardless of the cohort size.

Response: Thank you for the insightful and constructive comment. We agree with the comment, but evaluation of ATP/energy charge level or OCTN functions is extremely difficult in patients with cancer in clinical practice. Therefore, in accordance　with the academic editor's advice, we added the additional two cases and re-analyzed the data for all 20 patients. We believe that our present clinical data are valuable and worth publishing in PLOS ONE.

2\. The authors should provide information about treatment response and its relationship with the carnitine levels.

Response: In accordance with the comment, we have conducted an additional analysis about the relationship between the treatment response and carnitine levels.

The treatment responses were added to Table 1, and we discussed the relationship in the revised manuscript (lines 305--310) as follows: In addition, it is important to consider the type of patients who are recommended to receive carnitine supplementation. Because the baseline plasma AC/FC ratio in non-responders (SD and PD) tended to be higher compared with that of responders (CR and PR) (p = 0.057), it might be better to consider levocarnitine supplementation in patients with a high AC/FC ratio to retain the relative lenvatinib dose intensity.

3\. The comparison of AC/FC levels between sorafenib and lenvatinib would be of interest.

Response: We thank the Reviewer for this insightful comment. In accordance with this comment, we added the presumptive difference in the inhibitory effect on OCTN2 between lenvatinib and sorafenib, which would affect the AC/FC level, into the Discussion section of the revised manuscript (lines 275--278) as follows: However, because more fatigue was reported during lenvatinib therapy compared with sorafenib \[3\], it is possible that lenvatinib's inhibitory effect on OCTN2 is stronger compared with that of sorafenib.

4\. Although the BFI improved after the supplementation, AC/FC did not decrease. The authors conclude the well correlation between AC/FC and BFI during the treatment and they should discuss why this happened (why the AC/FC did not improve after the supplementation).

Response: We would like to express our strong appreciation to reviewer 2 for this comment. As the reviewer pointed out, the AC/FC ratio did not necessarily improve after the levocarnitine supplementation. We think that the placebo effect, including the recognition of dose reduction, might influence the BFI score especially in some patients with dose reduction. We provided this interpretation on lines 296--298 of the revised manuscript. Moreover, for reader's convenience, we have changed Figure 5, which separately shows patients with and without dose reduction.

\#Response to Journal Requirement

1\. We have checked that our manuscript meets STROBE statement.

2\. a) As pointed out, the notation has been changed as follows: This study was approved by the Ethics Review Board of Juntendo University Faculty of Medicine (Jundai-Irin No-2016135) and was performed in accordance with the 1964 Declaration of Helsinki and its later amendments.

b\) In accordance with the comment, we have inserted the same text to the "Ethics Statement".

3\. Thank you for pointing some minor occurrences of overlapping text. The notation has been changed as follows.

Lines 68--69: Patients with cancer occasionally experience fatigue and general malaise before and after treatment, which is described as cancer-related fatigue.

Line 98--99: This study was approved by the Ethics Review Board of Juntendo University Faculty of Medicine

Line 185--189: The box spans data between two quartiles (IQR, interquartile range), and the bold line represents the median. The ends of the whiskers represent the largest and smallest values that are not outliers.
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Carnitine insufficiency is associated with fatigue during lenvatinib treatment in patients with hepatocellular carcinoma

PLOS ONE

Dear Prof. Okubo,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Mar 06 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Tatsuo Kanda, M.D., Ph.D.

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Thank you for revising the problem.

The correlation coefficient between BFI and AC/FC ratio is increases from baseline to day 28 in Figure 4.

I think it is consistent because fatigue is relatively weak at baseline.

Revised manuscript satisfies my requirement.

Thank you.

Reviewer \#2: The authors have fulfilled each of the major compulsory revisions and modified the manuscript as requested. I have the following further suggestions that in my opinion will improve the quality of the manuscript.

In the study, authors measured urine/plasma AC/FC. The reviewer was wondering if they could describe which marker was the most useful in the real-world clinical setting: the reason, speculation, and how often it should be monitored. Please add this information in the discussion section.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0229772.r004
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\#Response to reviewer 2

1\. In the study, authors measured urine/plasma AC/FC. The reviewer was wondering if they could describe which marker was the most useful in the real-world clinical setting: the reason, speculation, and how often it should be monitored. Please add this information in the discussion section.

Response: Thank you for the insightful comment. In accordance with the comment, we discussed the utility of the plasma AC/FC ratio in the real-world clinical setting in the revised manuscript (lines 311--316) as follows: Throughout the study period, only the plasma AC/FC ratio among all of the markers (plasma FC, plasma AC, urine FC, urine AC levels, and urine AC/FC ratio) was associated with BFI (data not shown). Therefore, only the plasma AC/FC ratio seems to be a useful marker during lenvatinib therapy. As mentioned above, the baseline plasma AC/FC ratio seems to be useful for predicting incomplete treatment with lenvatinib.
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Dear Prof. Okubo,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

Authors should make a list of each patients\'characteristics and data by an excel file and submit the excel file as a supplementary file with manuscript again.

==============================

We would appreciate receiving your revised manuscript by Mar 21 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Tatsuo Kanda, M.D., Ph.D.

Academic Editor

PLOS ONE

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0229772.r006
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Dr. Tatsuo Kanda, Academic Editor

PLOS ONE

Dear Dr. Kanda,

Please find attached a copy of our revised manuscript titled "Carnitine insufficiency is associated with fatigue during lenvatinib treatment in patients with hepatocellular carcinoma", which we would like to resubmit for publication in PLOS ONE.

We would like to thank for the helpful comment. We have added a supplementary file including the patient characteristics and data, and we trust that our manuscript is now suitable for publication in your journal.

Yours sincerely,

Hironao Okubo, MD, PhD

Department of Gastroenterology

Juntendo University Nerima Hospital

\#Response to the academic editor

1\. Authors should make a list of each patients\' characteristics and data by an excel file and submit the excel file as a supplementary file with manuscript again.

Response: Thank you for the helpful comment. In accordance with the comment, we have added a supplementary file including the patient characteristics and data, and we trust that our manuscript is now suitable for publication in your journal. In addition, we have added the supporting information into the revised manuscript (lines 330--331) as follows:

Supporting information

S1 Data. Patient characteristics and data.
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Dear Dr. Okubo,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Tatsuo Kanda, M.D., Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

10.1371/journal.pone.0229772.r008
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Carnitine insufficiency is associated with fatigue during lenvatinib treatment in patients with hepatocellular carcinoma

Dear Dr. Okubo:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Tatsuo Kanda

Academic Editor

PLOS ONE
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